University of Cambridge > > Darwin College Science Seminars > Can anti-cancer immunotherapeutics be repurposed to kill parasites?

Can anti-cancer immunotherapeutics be repurposed to kill parasites?

Add to your list(s) Download to your calendar using vCal

If you have a question about this talk, please contact KC Sivaramakrishnan.

One of the key goals in the design of new anti-cancer therapeutics is to kill the cancer cells while limiting damage to the healthy cells of the body. In pursuit of this goal, anti-cancer antibody-drug conjugates (ADCs) are increasingly being developed. These immunotherapeutics concentrate the drug specifically inside the cancer cell by combining an antibody that targets the cancer cell surface with a cytotoxic drug.

In parallel, one of the goals in the design of novel therapeutics against protozoan parasites is to destroy the invading cells without causing damage to the host cells. It is logical, therefore, that ADCs could also provide a new class of therapeutic agents against protozoan pathogens. Further, there is clear scope for piggy-back drug development alongside anti-cancer ADCs by varying only cell-specificity.

I will discuss the use of the African trypanosome as a proof-of- principle model for the use of anti-cancer ADCs against parasites.

This talk is part of the Darwin College Science Seminars series.

Tell a friend about this talk:

This talk is included in these lists:

Note that ex-directory lists are not shown.


© 2006-2023, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity